

National Phase of PCT/US03/020829
In re: RASI et al.
Preliminary Amendment

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-10 (Cancelled)

11. (New) A method enhancing expression of tumor antigen comprising treating tumor cells with an amount of thymalfasin sufficient to increase expression of tumor antigen relative to that of untreated tumor cells.
12. (New) The method of claim 11, wherein the administration is to a patient *in vivo*.
13. (New) The method of claim 12, wherein the thymalfasin is administered at a dose between 2 µg/kg body weight and 6 mg/kg body weight.
14. (New) The method of claim 13, wherein the thymalfasin is administered at a dose between 20 µg/kg body weight and 200 µg/kg body weight.
15. (New) The method of claim 11 wherein said tumor antigen is TLP.
16. (New) A method for enhancing the sensitivity of a immunodiagnostic or immunotherapeutic method, comprising pre-treating target tumor cells by administering to the cells an amount of thymalfasin sufficient to increase the expression of tumor antigen relative to that of untreated tumor cells, followed by application of the immunodiagnostic or immunotherapeutic method.

17. (New) The method of claim 16, wherein the administration is to a patient *in vivo*.
18. (New) The method of claim 17, wherein the thymalfasin is administered at a dose between 2 µg/kg body weight and 6 mg/kg body weight.
19. (New) The method of claim 18, wherein the thymalfasin is administered at a dose between 20 µg/kg body weight and 200 µg/kg body weight.
20. (New) The method of claim 11 wherein the administration is to cells *in vitro*.
21. (New) The method of claim 16 wherein the administration is to cells *in vitro*.
22. (New) The method of claim 16 wherein said tumor antigen is TLP.